睿智医药与镁伽科技战略合作 股东减持引关注

Group 1 - The core viewpoint of the news is that Ruizhi Pharmaceutical's shareholders have reduced their holdings due to personal financial needs, while the company has entered a strategic partnership to enhance drug development efficiency through AI technology [1][2]. Group 2 - Shareholders Liang Yufeng and Yu Xianwen have collectively reduced their holdings by 1.3894 million shares, bringing their ownership below 5% [1]. - The company has signed a strategic cooperation agreement with Meijia Technology to build an "AI-driven automated laboratory for biomedicine," aiming to combine AI technology with preclinical research capabilities [1]. - In the past 7 trading days, Ruizhi Pharmaceutical's stock price has increased by 1.83%, with a high of 11.42 yuan and a low of 10.77 yuan, closing at 11.10 yuan on February 12 [2].